Neurodegenerative Diseases

News

VectorY has been cleared by the FDA to start human trials of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis cases.

R&D

On the emergence of brain organoids and the advent of automation, the latter being essential for high-throughput approaches drug development demands.

News

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

R&D

A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.

News

uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.

News

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.